Quick Answer
REVELATION BIOSCIENCES, INC. reported Net Income of -$8.91 million for fiscal year 2025.
REVELATION BIOSCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$8.91M +40.7% |
-$15.04M -12405.6% |
-$120.3K +98.9% |
-$10.83M +9.7% |
-$11.99M -635.2% |
-$1.63M -44718.6% |
| Diluted EPS | -$23.95 +97.7% |
-$1052.16 -12366.4% |
-$8.44 +94.3% |
-$149.20 -251.1% |
-$42.50 | — |
| Total Assets | $11.58M +74.9% |
$6.62M -45.8% |
$12.21M +121.9% |
$5.50M +169.5% |
$2.04M -97.2% |
$74.16M +327023.7% |
| Cash and Equivalents | $10.70M +64.6% |
$6.50M -45.8% |
$11.99M +128.3% |
$5.25M +312.1% |
$1.27M +10763.6% |
$11.7K |
| Stockholders Equity | $8.86M +88.2% |
$4.71M -29.2% |
$6.65M +531.6% |
$1.05M +1158.1% |
-$99.5K -102.9% |
$3.41M +93877.5% |
| R&D Expense | $4.06M +14.5% |
$3.55M -14.4% |
$4.15M -22.9% |
$5.38M -22.2% |
$6.91M | — |
| Operating Income | -$9.07M -13.7% |
-$7.98M +7.9% |
-$8.66M +20.3% |
-$10.86M +9.1% |
-$11.95M | — |
| Shares Outstanding | 1.58M +3539.1% |
43,526 +164.0% |
16,484 -78.7% |
77,375 -72.6% |
282,039 -84.5% |
1.82M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.91M | +14.9% | +22.0% |
| Diluted EPS | September 30, 2025 | -$1.77 | +95.6% | +74.8% |
| Total Assets | September 30, 2025 | $12.86M | +90.7% | +138.3% |
| Cash and Equivalents | September 30, 2025 | $12.71M | +94.3% | +145.6% |
| Stockholders Equity | September 30, 2025 | $11.00M | +311.5% | +187.6% |
| R&D Expense | September 30, 2025 | $922.9K | +11.1% | -30.0% |
| Operating Income | September 30, 2025 | -$1.94M | -8.1% | +21.1% |
| Shares Outstanding | September 30, 2025 | 3.59M | -16.5% | +133.7% |
- REVELATION BIOSCIENCES, INC. reported Net Income of -$8.91 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +40.7% in Net Income compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Diluted EPS of $23.95 per share (loss) for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +97.7% in Diluted EPS compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Total Assets of $11.58 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +74.9% in Total Assets compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Cash and Equivalents of $10.70 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +64.6% in Cash and Equivalents compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Stockholders Equity of $8.86 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +88.2% in Stockholders Equity compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported R&D Expense of $4.06 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +14.5% in R&D Expense compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Operating Income of -$9.07 million for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed a decrease of -13.7% in Operating Income compared to the prior fiscal year.
- REVELATION BIOSCIENCES, INC. reported Shares Outstanding of 1.58 million shares for fiscal year 2025.
- REVELATION BIOSCIENCES, INC. showed an increase of +3539.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: